Prescott et al. — Comorbidities, Weight-Based Fluid Resuscitation, and Sepsis Mortality

1. Publication

• Title: Comorbidities, Weight-Based Initial Fluid Resuscitation, and Mortality in Patients With Sepsis
• Acronym: None assigned
• Year & Journal: JAMA Network Open, 2026;9(6):e2618232
• Citation: Prescott HC, et al. Comorbidities, Weight-Based Initial Fluid Resuscitation, and Mortality in Patients With Sepsis. JAMA Netw Open. 2026;9(6):e2618232.

⚠️ Study Design Note

This is a large observational cohort study using weighted regression models to emulate a target trial — not a randomized controlled trial. It is included here because it directly informs the current (2026) Surviving Sepsis Campaign guideline's weight-based fluid recommendation, but its associational (not causal-trial) design must be weighted accordingly in interpretation.

2. Context & Rationale

Background: Guidelines suggest administering ≥30 mL/kg of initial fluid to patients with sepsis-induced hypoperfusion, but this recommendation carries low-certainty evidence, and uncertainty specifically remains about its net benefit in patients with severe cardiac or kidney disease who may be at elevated risk of fluid-overload harm.

Research Question/Hypothesis: Among adults hospitalized with community-onset sepsis, is administration of ≥30 mL/kg fluid within 6 hours of hospital arrival associated with lower 30-day mortality, and does this association differ by fluid indication (hypoperfusion vs intermediate lactate elevation) and presence of severe comorbidities that increase fluid-overload risk?

Why This Matters: The 30 mL/kg recommendation is applied broadly, including to patients with heart failure, severe aortic stenosis, or end-stage kidney disease, for whom the risk-benefit balance has been genuinely uncertain and undertested in prior trials (which largely excluded or underrepresented these patients).

3. Design & Methods

• Study Type: Retrospective cohort study using weighted regression models (target-trial-emulation approach), not a randomized trial
• Setting & Centers: Multicenter, community-onset sepsis hospitalizations (specific center count not detailed in available text)
• Population:
• Inclusion: 43,321 patients hospitalized for community-onset sepsis; 25,481 (58.8%) had an indication for fluid resuscitation and were included in the primary analysis. Median age 71y (IQR 61–80), 50.5% male, 37.0% with BMI >30
• Stratification: By (1) fluid indication — hypoperfusion (hypotension or lactate >36.0 mg/dL) vs intermediate lactate elevation (18.0–36.0 mg/dL) — and (2) presence of severe comorbidities that might increase fluid-overload risk (LVEF <40%, severe-to-critical aortic stenosis, or end-stage kidney disease)
• Subgroup sizes: Hypoperfusion without severe comorbidities: 12,943 (50.8%); hypoperfusion with severe comorbidities: 1,741 (6.8%); intermediate lactate elevation without severe comorbidities: 9,974 (39.1%); intermediate lactate elevation with severe comorbidities: 823 (3.2%)
• Exposure: Administration of ≥30 mL/kg fluid within 6 hours of hospital arrival (weight-based, actual or adjusted/ideal body weight per BMI)
• Comparator: <30 mL/kg fluid in the same window
• Analysis: Weighted regression models adjusted for patient characteristics; secondary analyses used adjusted logistic regression with restricted cubic splines to model dose-response
• Follow-Up: 30-day mortality

4. Key Results

Note on data completeness: Per the strict data-integrity standard for this handbook, the severe-comorbidity subgroup results (the study's most clinically novel contribution) are marked "not reported in accessible text" rather than estimated, since the full JAMA Network Open article was not directly accessible for exact extraction beyond the hypoperfusion-without-comorbidities figure above. Readers should consult the primary source (JAMA Netw Open. 2026;9(6):e2618232) directly for the comorbidity-stratified results before applying this study's comorbidity-specific conclusions clinically.

5. Internal Validity Assessment

• Randomization & Allocation: None — this is an observational study. Uses weighted regression (propensity/target-trial-emulation methodology) to approximate a randomized comparison, but residual and unmeasured confounding cannot be excluded.
• Protocol Adherence & Separation: Not applicable in the RCT sense; exposure (≥30 vs <30 mL/kg) reflects real-world clinical decision-making, which is itself likely influenced by illness severity and clinician risk perception (confounding by indication is a central threat).
• Blinding & Detection Bias: Not applicable (observational, retrospective).
• Missing Data & Sensitivity Analyses: Secondary restricted-cubic-spline dose-response analyses were used to strengthen causal inference beyond a simple binary threshold comparison.
• Overall Internal Validity Conclusion: Low-Moderate for causal inference — as an observational study, even with sophisticated weighting methodology, it cannot establish causation with the same confidence as a randomized trial. Confounding by indication (sicker patients more likely to receive aggressive fluid, or conversely, clinicians withholding fluid from perceived fluid-intolerant patients) is a fundamental, unresolvable limitation of this design.

6. External Validity Assessment

• Population Representativeness: Large sample (43,321 patients; 25,481 analyzed), community-onset sepsis, real-world hospital population — broadly representative of the population guidelines are meant to address, including specifically the comorbidity subgroups (heart failure, aortic stenosis, ESKD) that RCTs have typically excluded or underrepresented.
• Practice Context: Reflects real-world, non-protocolized fluid administration decisions rather than a standardized trial protocol.
• Overall External Validity Conclusion: High in terms of population representativeness (specifically filling the comorbidity-subgroup gap left by RCTs) but this must be weighed against the lower internal (causal) validity inherent to observational design.

7. Strengths & Limitations

Strengths:

• Very large sample size, enabling stratified analysis of clinically important but RCT-underrepresented subgroups (severe comorbidities)
• Target-trial-emulation methodology represents current best practice for observational causal inference
• Directly addresses a genuine, guideline-relevant evidence gap (fluid resuscitation in patients at risk of fluid-overload harm)
• Dose-response (spline) analyses complement the binary threshold comparison

Limitations:

• Observational design — cannot establish causation; confounding by indication is a fundamental threat that no amount of statistical adjustment can fully resolve
• The specific severe-comorbidity subgroup results (the study's most novel and clinically anticipated contribution) were not accessible in full detail for this summary
• Retrospective design subject to documentation/coding accuracy for comorbidities and fluid volumes

8. Interpretation & Practice Impact

• Clinical Implications: In patients with sepsis-induced hypoperfusion without severe comorbidities, weight-based fluid ≥30 mL/kg was associated with lower adjusted 30-day mortality — consistent with (and supportive of) current guideline recommendations for this population. The comorbidity-specific findings, which would most directly inform bedside decisions in heart failure/ESKD/severe AS patients, require direct consultation of the primary source given incomplete accessible data for this summary.
• Mechanistic Coherence: Consistent with the physiological rationale that hypoperfused (versus merely lactate-elevated) patients benefit more from volume expansion.
• Systems-Level Takeaway: Reinforces that current guideline-recommended weight-based fluid thresholds are evidence-supported in the general hypoperfusion population; comorbidity-specific protocol modifications should be based on the specific subgroup data in the primary publication.

9. Controversies & Subsequent Evidence

• Editorial Commentary/Debates: Sepsis guideline discussions (e.g., EMCrit interview with lead SSC guideline author Hallie Prescott) have specifically flagged tension between the SSC's ≥30 mL/kg conditional recommendation and ESICM guidance suggesting "up to" 30 mL/kg — a meaningful difference in framing (floor vs ceiling) that remains debated, with commentators noting an "inexplicable" jump from earlier 20 mL/kg framings and calling for a dedicated 20-vs-30 mL/kg RCT.
• Guideline Integration: Directly informs the 2026 Surviving Sepsis Campaign guideline's weight-based fluid recommendation (calculated on actual body weight, or adjusted/ideal body weight for BMI >30), which explicitly calls for individual patient characteristics and context to guide fluid volume selection — language this study's comorbidity-stratified design was intended to support.

10. Summary & Executive Takeaway

Summary: This observational cohort study of 43,321 (25,481 analyzed) community-onset sepsis patients found that ≥30 mL/kg fluid within 6 hours was associated with lower adjusted 30-day mortality in patients with hypoperfusion without severe comorbidities (26.0% vs 30.4%; adjusted difference −4.4 percentage points, 95% CI −6.1 to −2.7). The clinically pivotal severe-comorbidity subgroup results were not fully accessible for this summary and should be consulted directly in the primary source.

Overall Takeaway: This large, methodologically sophisticated observational study supports current weight-based fluid guidance in sepsis patients with hypoperfusion and without severe cardiac/renal comorbidities, while its comorbidity-specific findings — the piece most relevant to individualizing care in fluid-intolerant patients — require direct review of the full publication given incomplete data access for this handbook entry.

11. Bibliography

• Prescott HC, Antonelli M, Alhazzani W, et al. Surviving Sepsis Campaign: International guidelines for management of sepsis and septic shock 2026. Crit Care Med. 2026;54(4):725-812.
• Shapiro NI, Douglas IS, et al. Early restrictive or liberal fluid management for sepsis-induced hypotension (CLOVERS). N Engl J Med. 2023;388:499-510.
• Meyhoff TS, Hjortrup PB, et al. Restriction of intravenous fluid in ICU patients with septic shock (CLASSIC). N Engl J Med. 2022;386:2459-2470.